Loading patent…
AssigneesBaxter International Inc., Baxter Healthcare S.A.
InventorsBarrett Rabinow, Randy White, Chong-Son Sun, Joseph Chung Take Wong, James E. Kipp, Mark Doty, Christine L. Rebbeck, Pavlos Papadopoulos
Estimating the term…
The present invention relates to compositions of submicron- to micron-size particles of antimicrobial agents. More particularly the invention relates to a composition of an antimicrobial agent that renders the agent potent against organisms normally considered to be resistant to the agent. The composition comprises an aqueous suspension of submicron- to micron-size particles containing the agent coated with at least one surfactant selected from the group consisting of: ionic surfactants, non-ionic surfactants, biologically derived surfactants, and amino acids and their derivatives. The particles have a volume-weighted mean particle size of less than 5 μm as measured by laser diffractometry.
A method for treating a subject infected with Candida albicans strain c43, the method comprising the step of administering itraconazole to a subject infected with Candida albicans strain c43, wherein the Candida albicans strain c43 has a MIC greater than 8 μg/mL for itraconazole, wherein the itraconazole is formulated as an aqueous suspension of submicron- to micron-size particles containing itraconazole coated with at least one surfactant selected from the group consisting of ionic surfactants, non-ionic surfactants, surface-active biological molecules, and amino acids and their derivatives, and wherein the particles have a volume-weighted mean particle size of less than 5 μm as measured by laser diffractometry.
Dependencies are inferred from the claim text.